Nuvation Bio to Present Pivotal IBTROZI® Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-...
Clinical data demonstrate IBTROZI's unprecedented durability in TKI-naïve advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with median Duration of Response (DOR) now increased to 50 months as of August 2025 data cutoff Presentations …